XML 52 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)
12 Months Ended
Dec. 31, 2016
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT  
Schedule of Changes in Fair Value of Level 3 Liability
 The changes in the fair value of the Level 3 liability are as follows (in US dollars):

   
Warrants with
Down-Round Protection
 
   
December 31,
 
   
2016
   
2015
 
             
Balance, Beginning of the year
   
321,695
     
2,057,618
 
Warrants issued as consideration for placement services
   
308,239
     
-
 
Amount classified out of stockholders’ deficit and presented as Warrants with Down-Round Protection
   
341,662
     
-
 
Exchange of Series A Warrants pursuant to the “Most favored nation” provision
           
(1,586,831
)
Change in fair value of Warrants with Down-Round Protection
   
(289,626
)
   
(149,092
)
Balance, End of year
   
681,970
     
321,695
Schedule of Fair Value Assumptions Used
The key inputs used in the fair value calculations were as follows:

   
December 31,
2016
   
December 31,
2015
 
Dividend yield (%)
   
-
     
-
 
Expected volatility (%) (*)
   
56.59
     
105.14
 
Risk free interest rate (%)
   
0.92
     
0.99
 
Expected term of options (years) (**)
   
1.20
     
2.20
 
Exercise price (US dollars)
   
4.50
     
5.80
 
Share price (US dollars) (***)
   
2.38
     
2.31
 
Fair value (US dollars)
   
0.16
     
0.84
 

(*)
Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.
 
(**)
Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.
 
(***)
The Common Stock price, per share reflects the Company’s management’s estimation of the fair value per share of Common Stock as of December 31, 2016, and 2015. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units at December 31, 2016, as applicable to each reporting period.
Schedule of Stock Grants Activity
The following tables present a summary of the status of the grants to employees, officers and directors as of December 31, 2016, 2015 and 2014:
 
   
Number
   
Weighted
average
exercise
price (US$)
 
Year ended December 31, 2016
           
Balance outstanding at beginning of year
   
413,473
     
6.04
 
Granted
   
149,330
     
4.53
 
Balance outstanding at end of the year
   
562,803
     
5.64
 
Balance exercisable at the end of the year
   
334,735
     
5.81
 

 
   
Number
   
Weighted
average
exercise
price (US$)
 
Year ended December 31, 2015
           
Balance outstanding at beginning of year
   
450,847
     
5.85
 
Exercised
   
(19,769
)
   
1.82
 
Forfeited
   
(17,605
)
   
6.01
 
Balance outstanding at end of the year
   
413,473
     
6.04
 
Balance exercisable at the end of the year
   
293,736
     
5.95
 
 
   
Number
   
Weighted
average
exercise
price (US$)
 
Year ended December 31, 2014
           
Balance outstanding at beginning of year
   
414,847
     
5.74
 
Granted
   
44,000
     
7.00
 
Forfeited
   
(8,000
)
   
6.25
 
Balance outstanding at end of the year
   
450,847
     
5.85
 
Balance exercisable at the end of the year
   
302,360
     
5.58
 
 
Schedule of Stock Grants, by Exercise Price Range
The following tables summarize information about options outstanding at December 31, 2016:
 
Exercise
price (US$)
   
Outstanding at
December 31, 2016
   
Weighted
average
remaining
contractual
life (years)
   
Exercise
price (US$)
   
Exercisable at
December 31, 2016
   
Weighted
average
remaining
contractual
life (years)
 
                                 
 
1.72
     
21,758
     
0.60
     
1.72
     
21,758
     
0.60
 
 
3.63
     
3,730
     
0.60
     
3.63
     
3,730
     
0.60
 
 
6.01
     
4,273
     
1.03
     
6.01
     
4,273
     
1.03
 
 
6.25
     
351,712
     
5.19
     
6.25
     
236,975
     
5.19
 
 
7.00
     
32,000
     
7.50
     
7.00
     
32,000
     
7.50
 
 
4.75
     
16,000
     
9.01
     
4.75
     
6,000
     
9.01
 
 
4.50
     
79,998
     
9.21
     
4.50
     
30,000
     
9.21
 
 
4.50
     
53,332
     
9.88
     
4.50
     
-
     
9.88
 
         
562,803
                     
334,736
         
Schedule of Assumptions Used to Value Options
The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model.  The following are the data and assumptions used:
 
   
2016
   
2015
   
2014
 
Dividend yield (%)
   
0
     
-
     
0
 
Expected volatility (%) (*)
   
62.16
     
-
     
105.14
 
Risk free interest rate (%)
   
1.08
     
-
     
1.61
 
Expected term of options (years) (**)
   
6
     
-
     
5-6
 
Exercise price (US dollars)
   
4.50, 4.75
     
-
     
7.00
 
Stock price (US dollars) (***)
   
2.38
     
-
     
2.31
 
Fair value (US dollars)
   
1.01, 098
     
-
     
1.59
 

(*)
Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.
 
 
(**)
Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.
 
(***)
The Common Stock price, per share for the year ended December 31, 2014 and 2016 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering. In reaching its estimation for December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units.